Transpl Int Transplant International Transpl Int 1432-2277 Frontiers Media S.A. 11073 10.3389/ti.2022.11073 Health Archive Correction Corrigendum: Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice Lopez-Martinez et al. Corrigendum: Enteric-Budesonide in Transplant and Native IgAN Lopez-Martinez Marina 1 2 Torres Irina 1 2 Bermejo Sheila 1 2 Moreso Francesc 1 2 * Garcia-Carro Clara 3 4 Vergara Ander 1 2 Ramos Natalia 1 2 Perello Manel 1 2 Gabaldon Alejandra 2 5 Azancot M. Antonieta 1 2 Bolufer Monica 1 2 Toapanta Nestor 1 2 Bestard Oriol 1 2 Agraz-Pamplona Irene 1 2 † Soler Maria Jose 1 2 * † 1 Department of Nephrology, Vall d’Hebron University Hospital, Barcelona, Spain 2 Centro de Referencia en Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), Vall d’Hebron University Hospital, Barcelona, Spain 3 Department of Nephrology, San Carlos Clinical University Hospital, Madrid, Spain 4 Centro de Referencia en Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), San Carlos Clinical University Hospital, Madrid, Spain 5 Department of Pathology, Vall d’Hebron University Hospital, Barcelona, Spain *Correspondence: Francesc Moreso, fjmoreso@vhebron.net; Maria Jose Soler, mjsoler01@gmail.com

These authors share senior authorship

 05 01 2023 2022 35 11073 22 11 2022 07 12 2022 Copyright © 2023 Lopez-Martinez, Torres, Bermejo, Moreso, Garcia-Carro, Vergara, Ramos, Perello, Gabaldon, Azancot, Bolufer, Toapanta, Bestard, Agraz-Pamplona and Soler. 2023 Lopez-Martinez, Torres, Bermejo, Moreso, Garcia-Carro, Vergara, Ramos, Perello, Gabaldon, Azancot, Bolufer, Toapanta, Bestard, Agraz-Pamplona and Soler

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice by Lopez-Martinez M, Torres I, Bermejo S, Moreso F, Garcia-Carro C, Vergara A, Ramos N, Perello M, Gabaldon A, Azancot MA, Bolufer M, Toapanta N, Bestard O, Agraz-Pamplona I and Soler MJ (2022). Transpl Int. 35:10693. doi: 10.3389/ti.2022.10693 IgA nephropathy IgAN recurrence in transplant kidney proteinuria reduction TRF-budesonide CKD progression

In the original article, there was a mistake in Table 1 as published. Since publication, it has been noticed that the rows “BMI (Kg/m2)” and “LDL (mg/dl)” incorrectly contained repeated data. The corrected version of Table 1 is shown below.

Change from baseline of analytical parameters.

Baseline 3 months 6 months 12 months 24 months
UPCR native-kidney (Relative decrease %) 1.2 (0.70–2.80) 0.81 (0.8–0.93) ‒32.5 0.53 (0.18–0.85) ‒55.8 1.10 (0.16–1.35) ‒8.3 0.74 (0.30–1.70) ‒38.3
UPCR transplant-kidney (Relative decrease %) 1.5 (0.78–4.3) 1.1 (0.39–1.55)* ‒26.7 0.59 (0.17–1.40) ‒60.7 0.75 (0.16–1.33) ‒50.0 1.27 (0.55–1.70) ‒15.3
UPCR total (Relative decrease %) 1.3 (0.72–4.23) 0.87 (0.54–1.18)* ‒33.1 0.59 (0.17–0.85)* ‒54.6 1.10 (0.21–1.30) ‒15.4 0.92 (0.36–1.83) ‒29.2
Creatinine (mg/dl) 1.66 ± 0.83 1.89 ± 1.62 1.41 ± 0.53 1.37 ± 0.60 1.78 ± 0.49
CKD-EPI (ml/min) 57.14 ± 24.49 57.07 ± 27.71 62.33 ± 23.00 65.63 ± 25.39 57.40 ± 25.47
Haematuria (yes %) 9 (69.2) 8 (61.5) 5 (50) 6 (75) 5 (100)
BMI (kg/m2) 27.19 ± 6.70 26.25 ± 6.49 28.95 ± 7.68 23.93 ± 2.06 23.3 ± 2.48
LDL (mg/dl) 112.73 ± 50.53 99.18 ± 31.74 91.63 ± 25.89 101.67 ± 39.64 108.40 ± 38.06
HbA1c (%) 5.89 ± 0.98 5.40 ± 0.30 6.07 ± 1.57 5.53 ± 0.85 5.22 ± 0.40
Clinical adverse events (yes %) 0 0 0 0 0

Median values (interquartile range 25/75 within parentheses) and relative decrease percentage of urine protein to creatinine ratio (UPCR), mean values (SD) of creatinine and estimated glomerular filtration rate by Chronic Kidney Disease Epidemiology Collaboration Equation (CKD-EPI), presence of haematuria, body mass index (BMI), low density lipoprotein (LDL), HbA1c, and clinical adverse events before and after 3-, 6-, 12-, and 24-month treatment with budesonide was started. *p < 0.05 versus baseline.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.